Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial.

被引：0
|
作者：
Meluch, AA
Spigel, DS
Greco, FA
Barton, JH
Messina, G
Gould, B
Rovito, MA
Hainsworth, JD
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[2] Wellstar Hlth Syst Canc Res, Marietta, GA USA
[3] Consultants Med Oncol & Hematol, Drexel Hill, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：436S / 436S
页数：1
相关论文
共 50 条
  • [11] Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: A phase II trial of the minnie pearl cancer research network
    Hainsworth, John D.
    Meluch, Anthony A.
    Spigel, David R.
    Yost, Kathleen
    Meng, Christina
    Greco, E. Anthony
    CLINICAL GENITOURINARY CANCER, 2006, 4 (04) : 287 - 292
  • [12] A phase II study of weekly docetaxel (T), estramustine (E), and celecoxib (C) in patients with hormone refractory prostate cancer (HRPC).
    Mellado, B
    Font, A
    Carles, J
    Catalán, G
    Larriba, JLG
    Gallardo, E
    Fernández, LA
    Nogué, M
    Lianes, P
    Del Alba, AG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 434S - 434S
  • [13] Weekly docetaxel and estramustine monaphosphate (EMP) in the treatment of patients with prostate cancer and persistent/recurrent PSA elevation following primary therapy: A phase II trial of the Minnie Pearl Cancer Research Network.
    Mainwaring, MG
    Meluch, AA
    Greco, FA
    Gian, VG
    Kohler, PC
    Lahiry, AK
    Gandhi, JG
    Morrissey, LH
    Hainsworth, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 446S - 446S
  • [14] Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: A minnie pearl cancer research network phase II trial
    Hainsworth, John D.
    Yardley, Denise A.
    Spigel, David R.
    Meluch, Anthony A.
    Rinaldi, David
    Schnell, Frederick M.
    Greco, F. Anthony
    CANCER INVESTIGATION, 2006, 24 (05) : 469 - 473
  • [15] Weekly docetaxel versus Docetaxel/Gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer - A Randomized phase 3 trial of the minnie pearl cancer research network
    Hainsworth, John D.
    Spigel, David R.
    Farley, Cindy
    Shipley, Dianna L.
    Bearden, James D.
    Gandhi, Jitendra
    Houston, Gerry Ann
    Greco, F. Anthony
    CANCER, 2007, 110 (09) : 2027 - 2034
  • [16] The addition of imatinib mesylate to estramustine/docetaxel (E/D) for the treatment of hormone refractory prostate cancer (HRPC) patients: Results of a phase I trial.
    Randall, M
    Rini, B
    Ryan, C
    Rosenberg, J
    Garcia, J
    Bubley, G
    Small, EJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 411S - 411S
  • [17] Low dose docetaxel, estramustine and thalidomide followed by maintenance thalidomide for the treatment of hormone refractory prostate cancer (HRPC): A phase II community based trial.
    Frank, RC
    Coscia, A
    Versea, L
    Cohen, N
    Zelkowitz, R
    Ruskin, A
    Skeris, A
    Dodds, P
    Nair, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 426S - 426S
  • [18] Phase II trial of weekly docetaxel, zoledronic acid and selenium for hormone refractory prostate cancer
    Kattan, J. G.
    Ghosn, M.
    Chahine, G.
    Saroufim, A.
    Nasr, F.
    Farhat, F. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [19] Weekly bolus topotecan as secondary therapy in extensive stage small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial.
    Peacock, NW
    Hainsworth, JD
    Switzer, AB
    Burris, HA
    Barrett, C
    Nicolau, MF
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 685S - 685S
  • [20] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    Investigational New Drugs, 2008, 26 : 75 - 79
12345